Proteome Sciences PLC (GB:PRM)
LSE:PRM
Want to see GB:PRM full AI Analyst Report?
PRM Stock Chart & Stats
2.85 p
-0.10 p(-2.84%)
At close: 4:00 PM EST
2.85 p
-0.10 p(-2.84%)
Day’s Range― - ―
52-Week Range1.20 p - 4.40 p
Previous CloseN/A
Volume41.42K
Average Volume (3M)476.64K
Market Cap
£5.26M
Enterprise Value19.32M
Total Cash (Recent Filing)£781.00K
Total Debt (Recent Filing)£15.77M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume209,671
30 Day Avg. Volume476,642
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Proteomics CapabilitiesProteome Sciences’ specialized proteomics and mass-spectrometry services address a technical, high-barrier niche used in drug discovery and biological research. This expertise creates durable, differentiated service offerings that support repeat engagements from pharma, biotech and academia over the medium term.
Improving Cash Generation TrendOperating cash flow moving close to breakeven in 2025 and materially smaller free cash flow outflow versus 2024 indicates improving operational cash conversion. If sustained, this reduces near-term refinancing pressure and supports gradual stabilization of operations over the next several quarters.
Asset-light Contract Research ModelA services-led, contract research business is typically less capital intensive than product manufacturing. The asset-light model can enable margin improvement with higher utilization, flexible cost structure, and scalability of revenue from recurring projects or multi-phase studies as client pipelines expand.
Bears Say
Declining Revenue TrendA meaningful year-over-year revenue decline erodes scale and undermines the company’s ability to absorb fixed lab costs. Continued top-line contraction would pressure utilization, weaken pricing leverage with customers, and make it harder to turn incremental revenues into profit over coming quarters.
Negative Gross Profit And Sustained LossesNegative gross profit signals current pricing or cost structure cannot cover direct lab costs. Large operating and net losses imply structural margin deficiencies; absent revenue recovery or cost realignment, the business faces persistent profitability headwinds that impair reinvestment and long-term viability.
Stressed Balance Sheet And LeverageHigh debt combined with deeply negative equity creates refinancing and solvency risk. Limited balance-sheet flexibility raises the likelihood of dilution or costly financing, reducing strategic optionality and making it harder to invest in growth or weather further revenue softness over the medium term.
Proteome Sciences News
PRM FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 1.20 p and its highest was 4.40 p in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is £5.26M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Jul 23, 2026 which is in 62 days.
How were Proteome Sciences PLC’s earnings last quarter?
Proteome Sciences PLC released its earnings results on Apr 15, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Proteome Sciences PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in GB:PRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
Technical Analysis
Options Prices
Currently, No data available
---